Frequently Asked Questions
The market is segmented based on , By Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, Alum, and Others), Route of Administration (Intramuscular Route, Subcutaneous Route, Intranasal Route, Oral Route, Intradermal Route, and Others), Disease Type (Infectious Diseases, Cancer and Others), Application (Research Application and Commercial Application), Application Category (Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants), End-User (Pediatric, Adults, and Others) – Industry Trends and Forecast to 2030.
.
The Global Vaccine Adjuvants Market size was valued at USD 1350.60 USD Million in 2022.
The Global Vaccine Adjuvants Market is projected to grow at a CAGR of 13.37% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer, GlaxoSmithKline, AstraZeneca, Abbott, 3M, Adjuvatis, Merck KGaA, Croda International, Novavax, InvivoGen, CSL Limited, SPI Pharma, Phibro Animal Health Corporation, SEPPIC, Agenus , OZ Biosciences, Kineta, Vaxine, Astellas Pharma, CureVac AG, Bavarian Nordic.
The market report covers data from the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.
